Profiling Prediction of Kinase Inhibitors: Toward the Virtual Assay.
暂无分享,去创建一个
B. Merget | S. Turk | Sameh Eid | F. Rippmann | S. Fulle
[1] Nathalie Japkowicz,et al. The Class Imbalance Problem: Significance and Strategies , 2000 .
[2] D. Manallack,et al. Selecting Screening Candidates for Kinase and G Protein‐Coupled Receptor Targets Using Neural Networks. , 2002 .
[3] P. Cohen. Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.
[4] Nitesh V. Chawla,et al. SMOTE: Synthetic Minority Over-sampling Technique , 2002, J. Artif. Intell. Res..
[5] Robert P. Sheridan,et al. Random Forest: A Classification and Regression Tool for Compound Classification and QSAR Modeling , 2003, J. Chem. Inf. Comput. Sci..
[6] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[7] Xiaoyang Xia,et al. Classification of kinase inhibitors using a Bayesian model. , 2004, Journal of medicinal chemistry.
[8] L. Wodicka,et al. A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.
[9] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[10] P. Zarrinkar,et al. High-throughput kinase profiling as a platform for drug discovery , 2008, Nature Reviews Drug Discovery.
[11] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[12] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[13] S. Knapp,et al. The (un)targeted cancer kinome. , 2010, Nature chemical biology.
[14] Geoffrey E. Hinton,et al. Rectified Linear Units Improve Restricted Boltzmann Machines , 2010, ICML.
[15] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[16] Theonie Anastassiadis,et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.
[17] Gaël Varoquaux,et al. Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..
[18] H. Yabuuchi,et al. Analysis of multiple compound–protein interactions reveals novel bioactive molecules , 2011, Molecular systems biology.
[19] Jay Yagnik,et al. The power of comparative reasoning , 2011, 2011 International Conference on Computer Vision.
[20] Mindy I. Davis,et al. Comprehensive analysis of kinase inhibitor selectivity , 2011, Nature Biotechnology.
[21] P. Hajduk,et al. Navigating the kinome. , 2011, Nature chemical biology.
[22] Eric J. Martin,et al. Profile-QSAR: A Novel meta-QSAR Method that Combines Activities across the Kinase Family To Accurately Predict Affinity, Selectivity, and Cellular Activity , 2011, J. Chem. Inf. Model..
[23] Peter S. Kutchukian,et al. Rethinking molecular similarity: comparing compounds on the basis of biological activity. , 2012, ACS chemical biology.
[24] Bin Chen,et al. Comparison of Random Forest and Pipeline Pilot Naïve Bayes in Prospective QSAR Predictions , 2012, J. Chem. Inf. Model..
[25] George Karypis,et al. Improved Machine Learning Models for Predicting Selective Compounds , 2012, J. Chem. Inf. Model..
[26] R. Daly,et al. Targeting the human kinome for cancer therapy: current perspectives. , 2012, Critical reviews in oncogenesis.
[27] M. McHugh. Interrater reliability: the kappa statistic , 2012, Biochemia medica.
[28] Michael J. Keiser,et al. Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.
[29] Sereina Riniker,et al. Heterogeneous Classifier Fusion for Ligand-Based Virtual Screening: Or, How Decision Making by Committee Can Be a Good Thing , 2013, J. Chem. Inf. Model..
[30] Andreas Bender,et al. Are phylogenetic trees suitable for chemogenomics analyses of bioactivity data sets: the importance of shared active compounds and choosing a suitable data embedding method, as exemplified on Kinases , 2013, Journal of Cheminformatics.
[31] Stephan C. Schürer,et al. Kinome-wide Activity Modeling from Diverse Public High-Quality Data Sets , 2013, J. Chem. Inf. Model..
[32] Dario R Alessi,et al. Kinase drug discovery--what's next in the field? , 2013, ACS chemical biology.
[33] R. Guha,et al. Profile of the GSK Published Protein Kinase Inhibitor Set Across ATP-Dependent and-Independent Luciferases: Implications for Reporter-Gene Assays , 2013, PloS one.
[34] Martin Augustin,et al. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery. , 2013, The Biochemical journal.
[35] Julian Blagg,et al. A public-private partnership to unlock the untargeted kinome. , 2013, Nature chemical biology.
[36] A. Vulpetti,et al. Comparability of Mixed IC50 Data – A Statistical Analysis , 2013, PloS one.
[37] Tao Xu,et al. Making Sense of Large-Scale Kinase Inhibitor Bioactivity Data Sets: A Comparative and Integrative Analysis , 2014, J. Chem. Inf. Model..
[38] M. Helmer-Citterich,et al. Computational methods for analysis and inference of kinase/inhibitor relationships , 2014, Front. Genet..
[39] Nitish Srivastava,et al. Dropout: a simple way to prevent neural networks from overfitting , 2014, J. Mach. Learn. Res..
[40] D. Fabbro,et al. Advances in kinase targeting: current clinical use and clinical trials. , 2014, Trends in pharmacological sciences.
[41] Marc C. Nicklaus,et al. QSAR Modeling of Imbalanced High-Throughput Screening Data in PubChem , 2014, J. Chem. Inf. Model..
[42] Anne Mai Wassermann,et al. A screening pattern recognition method finds new and divergent targets for drugs and natural products. , 2014, ACS chemical biology.
[43] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[44] S. Knapp,et al. Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery? , 2014, ACS chemical biology.
[45] Yuan Wang,et al. Using Information from Historical High-Throughput Screens to Predict Active Compounds , 2014, J. Chem. Inf. Model..
[46] Robert P. Sheridan,et al. Deep Neural Nets as a Method for Quantitative Structure-Activity Relationships , 2015, J. Chem. Inf. Model..
[47] Andreas Mayr,et al. Deep Learning as an Opportunity in Virtual Screening , 2015 .
[48] N. Heinrich,et al. Computational Chemistry in the Pharmaceutical Industry: From Childhood to Adolescence , 2015, ChemMedChem.
[49] P. Prusis,et al. Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects , 2015 .
[50] Friedrich Rippmann,et al. Pocketome of Human Kinases: Prioritizing the ATP Binding Sites of (Yet) Untapped Protein Kinases for Drug Discovery , 2015, J. Chem. Inf. Model..
[51] John P. Overington,et al. Comprehensive characterization of the Published Kinase Inhibitor Set , 2016, Nature Biotechnology.
[52] Alina Bora,et al. Predictive Models for Fast and Effective Profiling of Kinase Inhibitors , 2016, J. Chem. Inf. Model..
[53] M. Clausen,et al. Small-molecule kinase inhibitors: an analysis of FDA-approved drugs. , 2016, Drug discovery today.
[54] Martín Abadi,et al. TensorFlow: Large-Scale Machine Learning on Heterogeneous Distributed Systems , 2016, ArXiv.
[55] Álvaro Cortés Cabrera,et al. Compound biological signatures facilitate phenotypic screening and target elucidation , 2016, bioRxiv.
[56] Friedrich Rippmann,et al. Identification and Visualization of Kinase-Specific Subpockets , 2016, J. Chem. Inf. Model..